Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Monopar Therapeutics Skyrockets 400% on Licensing Deal

Stock market chart

Monopar Therapeutics (NASDAQ: MNPR) saw its stock skyrocket over 400% on Thursday after announcing a licensing deal with AstraZeneca. By 2 PM, the stock had traded over 10 million shares, far above its usual daily volume of 800,000. 

This sudden surge in price and volume has caught the attention of many, driven by the news that Monopar will take over the global development and commercialization of a once-terminated Phase 3 drug candidate from AstraZeneca’s Alexion unit. With such extreme price action, many might wonder whether the recent rally is the start of a longer-term opportunity or just a short-term pop.

What is Monopar Therapeutics?

Monopar is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. Its lead product candidate, Validive, is in late-stage trials to prevent severe oral mucositis in cancer patients undergoing chemoradiotherapy. In addition, the company is advancing several other pipeline drugs, including Camsirubicin, which targets advanced soft tissue sarcoma, and MNPR-101, an antibody-based therapy designed for multiple cancers and severe COVID-19. Monopar’s research portfolio is ambitious, but the company has yet to report consistent revenue, making it a high-risk bet in the biotech space.

Monopar Secures Exclusive License

The stock’s dramatic move on Thursday came after Monopar announced it had secured an exclusive worldwide license to develop and commercialize ALXN-1840, a drug designed to treat Wilson’s disease, a rare genetic disorder that leads to toxic copper buildup in the liver, brain, and other organs. AstraZeneca had previously terminated the program after clinical trials failed to meet regulatory endpoints despite showing promise in earlier studies. Under the new agreement, Monopar will make upfront cash and equity payments to AstraZeneca, with additional costs tied to future regulatory milestones and sales performance.

Key Considerations Before Taking Action in MNPR

The recent rally has drawn interest from traders, but the extreme volatility also comes with risks. With a small float and typically low trading volume, Monopar’s shares are prone to sharp price swings. While Thursday’s surge is exciting, it could just as quickly reverse if momentum fades or profit-taking sets in.

Long-term investors may need to be cautious, especially given that the company has reported no revenue for the second quarter of 2024 and a net loss of $0.10 per share. The stock has a consensus Buy rating based on three analyst ratings, but the consensus price target of $22 suggests potential downside after the recent spike. It’s also worth noting that the consensus price target is primarily influenced by one outlier price target of $50 set by Rodman & Renshaw, with the other two price targets at $6 and $10, respectively.

Monopar’s ability to sustain this momentum will largely depend on how well it executes the development of ALXN-1840 and advances its other drug candidates. The company has regained Nasdaq compliance through a 5-for-1 reverse stock split and expanded its partnership with NorthStar Medical Radioisotopes, which will supply critical components for cancer treatment. These developments are encouraging, but the road ahead remains challenging, especially without steady revenue streams.

Should You Invest?

For now, Monopar offers an exciting, high-risk, high-reward opportunity for speculative traders who thrive on volatility. However, the recent rally may not be enough for long-term investors to offset the risks tied to the company’s financials and uncertain clinical timelines. Whether the partnership with AstraZeneca can unlock new value or if this surge is just a temporary spike will become more apparent as the company moves forward. Investors must stay alert to any new developments to determine if Monopar can capitalize on this fresh catalyst or if it remains a speculative trade best suited for short-term gains.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.